{"id":"de-089-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"},{"rate":"null","effect":"Cataract"},{"rate":"null","effect":"Glaucoma"}]},"_chembl":{"chemblId":"CHEMBL5814142","moleculeType":null,"molecularWeight":"375.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by suppressing the immune system's response to reduce inflammation and swelling in the eye. Corticosteroids like DE-089 are commonly used to treat conditions such as uveitis and conjunctivitis.","oneSentence":"DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:39.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-infectious uveitis affecting the posterior segment of the eye"},{"name":"Treatment of non-infectious keratitis and anterior uveitis"}]},"trialDetails":[{"nctId":"NCT03216096","phase":"PHASE1","title":"Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2017-09-08","conditions":"Dry Eye Disease","enrollment":20},{"nctId":"NCT01189032","phase":"PHASE2","title":"Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye","enrollment":320},{"nctId":"NCT01240382","phase":"PHASE3","title":"Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye","enrollment":332},{"nctId":"NCT01101984","phase":"NA","title":"Study of DE-089 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2010-02","conditions":"Dry Eye","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1907,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DE-089 ophthalmic solution","genericName":"DE-089 ophthalmic solution","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye, Treatment of non-infectious keratitis and anterior uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}